- Home
- PD vs BBIO Comparison
PD vs BBIO Comparison
Compare PD & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PD
- BBIO
- Stock Information
- Founded
- PD 2009
- BBIO 2015
- Country
- PD United States
- BBIO United States
- Employees
- PD N/A
- BBIO N/A
- Industry
- PD Computer Software: Prepackaged Software
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- PD Technology
- BBIO Health Care
- Exchange
- PD Nasdaq
- BBIO Nasdaq
- Market Cap
- PD 1.5B
- BBIO 10.4B
- IPO Year
- PD 2019
- BBIO 2019
- Fundamental
- Price
- PD $16.17
- BBIO $64.50
- Analyst Decision
- PD Hold
- BBIO Strong Buy
- Analyst Count
- PD 9
- BBIO 16
- Target Price
- PD $18.33
- BBIO $65.25
- AVG Volume (30 Days)
- PD 2.0M
- BBIO 2.1M
- Earning Date
- PD 11-25-2025
- BBIO 10-29-2025
- Dividend Yield
- PD N/A
- BBIO N/A
- EPS Growth
- PD N/A
- BBIO N/A
- EPS
- PD N/A
- BBIO N/A
- Revenue
- PD $483,608,000.00
- BBIO $235,812,000.00
- Revenue This Year
- PD $9.16
- BBIO $115.12
- Revenue Next Year
- PD $6.79
- BBIO $65.29
- P/E Ratio
- PD N/A
- BBIO N/A
- Revenue Growth
- PD 8.20
- BBIO 7.62
- 52 Week Low
- PD $13.70
- BBIO $21.72
- 52 Week High
- PD $21.98
- BBIO $65.00
- Technical
- Relative Strength Index (RSI)
- PD 52.60
- BBIO 74.82
- Support Level
- PD $15.50
- BBIO $52.75
- Resistance Level
- PD $16.40
- BBIO $65.00
- Average True Range (ATR)
- PD 0.40
- BBIO 2.06
- MACD
- PD 0.03
- BBIO 0.68
- Stochastic Oscillator
- PD 55.89
- BBIO 94.86
About PD PagerDuty Inc.
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.